McDonnell Boehnen Hulbert & Berghoff LLP partner Andrew W. Williams, Ph.D. authored an article entitled, “5 Questions To Ask About Biosimilars In 2016” that appears in the January 15, 2016 online edition of Biosimilar Development. 2015 was a breakthrough year for biosimilars. Not only did it see the launch of the first biosimilar, Zarxio, but the Federal Circuit provided its first interpretation of the Biologics Price Competition and Innovation Act (BPCIA). Nevertheless, there are still a lot of unanswered questions, many of which are likely to be addressed in 2016. View the article